Appili Therapeutics Inc. (APLIF)
- Previous Close
0.0000 - Open
0.0208 - Bid 0.0206 x 4000000
- Ask 0.0286 x --
- Day's Range
0.0208 - 0.0208 - 52 Week Range
0.0140 - 0.0370 - Volume
10,000 - Avg. Volume
63,450 - Market Cap (intraday)
2.632M - Beta (5Y Monthly) -0.25
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Jun 23, 2025 - Jun 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
appilitherapeutics.comRecent News: APLIF
View MorePerformance Overview: APLIF
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APLIF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APLIF
View MoreValuation Measures
Market Cap
2.60M
Enterprise Value
10.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
28.27
Price/Book (mrq)
--
Enterprise Value/Revenue
118.13
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-306.73%
Return on Equity (ttm)
--
Revenue (ttm)
124.75k
Net Income Avi to Common (ttm)
-3.96M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
186.17k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.67M